Solid-in-oil nanodispersions for intranasal vaccination: Enhancement of mucosal and systemic immune responses

Qingliang Kong, Momoko Kitaoka, Yoshiro Tahara, Rie Wakabayashi, Noriho Kamiya, Masahiro Goto

Research output: Contribution to journalArticle

Abstract

En masse vaccination is a promising strategy for combatting infectious diseases. Intranasal vaccination is a viable route of mass vaccination, and it could be performed easily via needle-free administration. However, it is not widely used because it tends not to evoke sufficient immunity. The aim of the present study was to improve the performance of intranasal vaccination by extending the amount of time that administered antigens remain in the nasal cavity, and enhancing immune responses via a nanocarrier-based adjuvant. A simple and safe solid-in-oil (S/O) system was investigated as a nanocarrier in intranasal vaccination. S/O nanodispersions are oil-based dispersions of antigens coated with surfactants. Because of the mucoadhesive capacities of surfactant and oil they have high potential to extend the amount of time that administered antigens remain in the nasal cavity, and can induce strong immune responses due to a nanocarrier-based adjuvant effect. In nasal absorption experiments antigens administered intranasally via S/O nanodispersions remained in the nasal cavity longer and induced strong mucosal and systemic immune responses. Histopathology analysis indicated that S/O nanodispersions did not modify the nasal epithelium or cilia, suggesting non-toxicity of the carrier. These results indicate the potential of intranasal vaccination using S/O nanodispersions for future vaccination.

Original languageEnglish
Article number118777
JournalInternational Journal of Pharmaceutics
Volume572
DOIs
Publication statusPublished - Dec 15 2019

Fingerprint

Mucosal Immunity
Oils
Vaccination
Nasal Cavity
Antigens
Surface-Active Agents
Mass Vaccination
Nasal Mucosa
Cilia
Needles
Communicable Diseases
Immunity

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Solid-in-oil nanodispersions for intranasal vaccination : Enhancement of mucosal and systemic immune responses. / Kong, Qingliang; Kitaoka, Momoko; Tahara, Yoshiro; Wakabayashi, Rie; Kamiya, Noriho; Goto, Masahiro.

In: International Journal of Pharmaceutics, Vol. 572, 118777, 15.12.2019.

Research output: Contribution to journalArticle

@article{64e4edcc8e8a4f04aa4e279647928dc2,
title = "Solid-in-oil nanodispersions for intranasal vaccination: Enhancement of mucosal and systemic immune responses",
abstract = "En masse vaccination is a promising strategy for combatting infectious diseases. Intranasal vaccination is a viable route of mass vaccination, and it could be performed easily via needle-free administration. However, it is not widely used because it tends not to evoke sufficient immunity. The aim of the present study was to improve the performance of intranasal vaccination by extending the amount of time that administered antigens remain in the nasal cavity, and enhancing immune responses via a nanocarrier-based adjuvant. A simple and safe solid-in-oil (S/O) system was investigated as a nanocarrier in intranasal vaccination. S/O nanodispersions are oil-based dispersions of antigens coated with surfactants. Because of the mucoadhesive capacities of surfactant and oil they have high potential to extend the amount of time that administered antigens remain in the nasal cavity, and can induce strong immune responses due to a nanocarrier-based adjuvant effect. In nasal absorption experiments antigens administered intranasally via S/O nanodispersions remained in the nasal cavity longer and induced strong mucosal and systemic immune responses. Histopathology analysis indicated that S/O nanodispersions did not modify the nasal epithelium or cilia, suggesting non-toxicity of the carrier. These results indicate the potential of intranasal vaccination using S/O nanodispersions for future vaccination.",
author = "Qingliang Kong and Momoko Kitaoka and Yoshiro Tahara and Rie Wakabayashi and Noriho Kamiya and Masahiro Goto",
year = "2019",
month = "12",
day = "15",
doi = "10.1016/j.ijpharm.2019.118777",
language = "English",
volume = "572",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",

}

TY - JOUR

T1 - Solid-in-oil nanodispersions for intranasal vaccination

T2 - Enhancement of mucosal and systemic immune responses

AU - Kong, Qingliang

AU - Kitaoka, Momoko

AU - Tahara, Yoshiro

AU - Wakabayashi, Rie

AU - Kamiya, Noriho

AU - Goto, Masahiro

PY - 2019/12/15

Y1 - 2019/12/15

N2 - En masse vaccination is a promising strategy for combatting infectious diseases. Intranasal vaccination is a viable route of mass vaccination, and it could be performed easily via needle-free administration. However, it is not widely used because it tends not to evoke sufficient immunity. The aim of the present study was to improve the performance of intranasal vaccination by extending the amount of time that administered antigens remain in the nasal cavity, and enhancing immune responses via a nanocarrier-based adjuvant. A simple and safe solid-in-oil (S/O) system was investigated as a nanocarrier in intranasal vaccination. S/O nanodispersions are oil-based dispersions of antigens coated with surfactants. Because of the mucoadhesive capacities of surfactant and oil they have high potential to extend the amount of time that administered antigens remain in the nasal cavity, and can induce strong immune responses due to a nanocarrier-based adjuvant effect. In nasal absorption experiments antigens administered intranasally via S/O nanodispersions remained in the nasal cavity longer and induced strong mucosal and systemic immune responses. Histopathology analysis indicated that S/O nanodispersions did not modify the nasal epithelium or cilia, suggesting non-toxicity of the carrier. These results indicate the potential of intranasal vaccination using S/O nanodispersions for future vaccination.

AB - En masse vaccination is a promising strategy for combatting infectious diseases. Intranasal vaccination is a viable route of mass vaccination, and it could be performed easily via needle-free administration. However, it is not widely used because it tends not to evoke sufficient immunity. The aim of the present study was to improve the performance of intranasal vaccination by extending the amount of time that administered antigens remain in the nasal cavity, and enhancing immune responses via a nanocarrier-based adjuvant. A simple and safe solid-in-oil (S/O) system was investigated as a nanocarrier in intranasal vaccination. S/O nanodispersions are oil-based dispersions of antigens coated with surfactants. Because of the mucoadhesive capacities of surfactant and oil they have high potential to extend the amount of time that administered antigens remain in the nasal cavity, and can induce strong immune responses due to a nanocarrier-based adjuvant effect. In nasal absorption experiments antigens administered intranasally via S/O nanodispersions remained in the nasal cavity longer and induced strong mucosal and systemic immune responses. Histopathology analysis indicated that S/O nanodispersions did not modify the nasal epithelium or cilia, suggesting non-toxicity of the carrier. These results indicate the potential of intranasal vaccination using S/O nanodispersions for future vaccination.

UR - http://www.scopus.com/inward/record.url?scp=85074332604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074332604&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2019.118777

DO - 10.1016/j.ijpharm.2019.118777

M3 - Article

C2 - 31678377

AN - SCOPUS:85074332604

VL - 572

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

M1 - 118777

ER -